These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 9042196)

  • 1. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
    Nishio K; Ishida T; Arioka H; Kurokawa H; Fukuoka K; Nomoto T; Fukumoto H; Yokote H; Saijo N
    Anticancer Res; 1996; 16(6B):3387-95. PubMed ID: 9042196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression.
    Kitagawa M; Higashi H; Takahashi IS; Okabe T; Ogino H; Taya Y; Hishimura S; Okuyama A
    Oncogene; 1994 Sep; 9(9):2549-57. PubMed ID: 8058318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of cisplatin on cell cycle regulators].
    Nishio K; Saijo N
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):289-94. PubMed ID: 8109984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.
    Hsu TS; Chen C; Lee PT; Chiu SJ; Liu HF; Tsai CC; Chao JI
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):799-808. PubMed ID: 18193228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells.
    Yin F; Giuliano AE; Law RE; Van Herle AJ
    Anticancer Res; 2001; 21(1A):413-20. PubMed ID: 11299771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL; Hwang J; Perng RP; Whang-Peng J
    Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers.
    Roberson RS; Kussick SJ; Vallieres E; Chen SY; Wu DY
    Cancer Res; 2005 Apr; 65(7):2795-803. PubMed ID: 15805280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
    Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
    Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
    Chang JY; Chang CY; Kuo CC; Chen LT; Wein YS; Kuo YH
    Mol Pharmacol; 2004 Jan; 65(1):77-84. PubMed ID: 14722239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase.
    Kitagawa M; Okabe T; Ogino H; Matsumoto H; Suzuki-Takahashi I; Kokubo T; Higashi H; Saitoh S; Taya Y; Yasuda H
    Oncogene; 1993 Sep; 8(9):2425-32. PubMed ID: 8395680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cell cycle regulation by anticancer agent].
    Nomoto T; Nishio K; Saijo N
    Gan To Kagaku Ryoho; 1995 Oct; 22(12):1719-23. PubMed ID: 7574801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
    Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells.
    Poon RY; Chau MS; Yamashita K; Hunter T
    Cancer Res; 1997 Nov; 57(22):5168-78. PubMed ID: 9371520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 kinase activity.
    Arita Y; Buffolino P; Coppock DL
    Exp Cell Res; 1998 Aug; 242(2):381-90. PubMed ID: 9683525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts.
    Someya A; Tanaka N; Okuyama A
    Biochem Biophys Res Commun; 1994 Jan; 198(2):536-45. PubMed ID: 8297363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
    Funayama Y; Nishio K; Takeda Y; Kubota N; Ohira T; Ohmori T; Ohta S; Ogasawara H; Hasegawa S; Saijo N
    Anticancer Res; 1993; 13(6A):1981-8. PubMed ID: 8297104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
    Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
    Lei W; Mayotte JE; Levitt ML
    Anticancer Res; 1999; 19(1A):221-8. PubMed ID: 10226546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.